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Background: The OptEC trial aims to evaluate the effectiveness of oral iron in young children with non-anemic iron
deficiency (NAID). The initial sample size calculated for the OptEC trial ranged from 112–198 subjects. Given the un-
certainty regarding the parameters used to calculate the sample, an internal pilot study was conducted. The objec-
tives of this internal pilot study were to obtain reliable estimate of parameters (standard deviation and design
factor) to recalculate the sample size and to assess the adherence rate and reasons for non-adherence in children
enrolled in the pilot study.
Methods: The first 30 subjects enrolled into the OptEC trial constituted the internal pilot study. The primary
outcome of the OptEC trial is the Early Learning Composite (ELC). For estimation of the SD of the ELC, descriptive
statistics of the 4 month follow-up ELC scores were assessed within each intervention group. The observed SD
within each group was then pooled to obtain an estimated SD (S2) of the ELC. Correlation (ρ) between the ELC
measured at baseline and follow-up was assessed. Recalculation of the sample size was performed using analysis of
covariance (ANCOVA) method which uses the design factor (1- ρ2). Adherence rate was calculated using a parent
reported rate of missed doses of the study intervention.
Conclusion: The new estimate of the SD of the ELC was found to be 17.40 (S2). The design factor was (1- ρ2) = 0.21.
Using a significance level of 5 %, power of 80 %, S2 = 17.40 and effect estimate (Δ) ranging from 6–8 points, the
new sample size based on ANCOVA method ranged from 32–56 subjects (16–28 per group). Adherence ranged
between 14 % and 100 % with 44 % of the children having an adherence rate ≥86 %. Information generated from
our internal pilot study was used to update the design of the full and definitive trial, including recalculation of
sample size, determination of the adequacy of adherence, and application of strategies to improve adherence.
Trial registration: ClinicalTrials.gov Identifier: NCT01481766 (date of registration: November 22, 2011).
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Background
This update reports the findings from an internal pilot
study that aimed to obtain parameter estimates for recal-
culation of the sample size of the OptEC trial (Optimizing
Early Child Development in the Primary Care Practice
Setting) and also assess the adherence rate of the partici-
pants in the internal pilot study.
The OptEC trial aims to evaluate the effectiveness of oral
iron plus nutritional guidance over placebo plus nutritional
guidance in children with non-anemic iron deficiency
(NAID) in improving their developmental, hematological
and behavioral outcomes. Sample size for the OptEC trial
ranged from 112–198 (Na) participants (using a standard
deviation, S1 = 15 and a range of effect estimates, Δ of 6–8
points). The sample size was calculated using the t-test. A
detailed description of the OptEC trial has previously been
published [1].
The design of the OptEC trial includes an internal
pilot study [2]. The rationale for conducting an internal
pilot for the OptEC trial was three fold. First, there was
uncertainty regarding the parameters used to calculate
the sample size for the OptEC trial [3]. The estimates
used were obtained from previous trials which had differ-
ent study conditions, for example, different population,
small numbers of centers and different treatment dur-
ation. Thus, prior estimates may not be representative of
the current trial. Inaccurate estimates may lead to an un-
necessarily large trial or a trial not large enough to have
sufficient power for detection of a clinically relevant treat-
ment effect. Data generated from internal pilots are used
to obtain more reliable estimates of parameters for recal-
culation of sample size of clinical trials [3–6].
Second, we aimed to recalculate the sample size for
the OptEC trial using the method known as the
ANCOVA (analysis of covariance). One advantage of the
ANCOVA method is that it accounts for the correlation
between the baseline and follow-up assessment of the
primary outcome, in the calculation of the sample size
[7]. Thus the sample size calculated using this method
will have the same power as the t-test but will require
fewer subjects [7]. In order to use the ANCOVA
method, we need to know the correlation between the
baseline and follow-up assessment of the primary out-
come of the OptEC trial which we intend to calculate
using our internal pilot data.
Third, evidence suggests low level of adherence to in-
terventions in clinical trials investigating the efficacy of
oral iron interventions [8]. A review of adherence in pri-
mary school children showed the adherence rate to oral
iron to range between 50 %-90 % [9]. Lack of adherence
may decrease the probability of detecting treatment dif-
ferences and affect the interpretation of observed differ-
ences. However, partial adherence is usually sufficient toevaluate the effectiveness of an intervention. According
to previous research, if 40 % of the participants in a ran-
domized trial have at least 90 % of adherence then the
effectiveness assessment process remains unimpaired
[10]. Data from an internal pilot study can be used to
check the level of adherence in participants of clinical
trials [11–13]. If adherence is found to be less then de-
sired, then strategies can be implemented to improve
adherence.
The overall aim of the internal pilot was to inform the
design of the full and definitive trial. Thus, the objectives
of the internal pilot study were (1) to obtain a reliable esti-
mate of the standard deviation (S2) of the primary outcome
of the OptEC trial; (2) to obtain the correlation between
the baseline and follow-up measurement of the primary
outcome; (3) to recalculate the sample size (Nr) of the
OptEC trial using the estimates generated from the in-
ternal pilot; and (4) to assess the adherence rate and causes
of non-adherence in children enrolled in the pilot study.
At the end of the pilot study, if necessary the sample
size will be recalculated and compliance measures may
need to be enhanced. Otherwise, the OptEC trial will
continue following the protocol as previously reported
[1]. During the collection and analysis of data for the in-
ternal pilot study the recruitment of the trial continued.
Methods
The internal pilot study is an integral part of the OptEC
trial, which consisted of the first few participants en-
rolled in the trial. Hence, it follows the same design
and conduct of the main trial. In the following sections
we describe methods that are particularly relevant to
the internal pilot study as recommended by Thabane
et al. for reporting of pilot study results [14].
Design
The OptEC trial, hence the internal pilot study was a
multi-site, pragmatic, placebo controlled, superiority
randomized trial [1].
Participants
Eligibility criteria for participation in the internal pilot
were the same as those for the OptEC trial. Inclusion cri-
teria: children with NAID [hemoglobin >110 g/L, serum
ferritin < 14 μg/L and C-reactive protein (CRP) <10 mg/L];
and age 12 to 40 months. Exclusion criteria: CRP level
>10 mg/L, previously diagnosed developmental disorder,
genetic, chromosomal or syndromic condition, chronic
medical conditions (except asthma and allergies), includ-
ing chronic anemia, recent oral iron supplementation or
treatment, gestational age less than 35 weeks, low birth
weight less than 2500 grams, attending the office for an
acute illness, any contraindications to receiving elemental
iron, the use of any natural health product containing the
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uct, English not spoken to the child in the home or in a
child care setting.
Intervention and control
Children are randomized to receive either oral iron treat-
ment (6 mg elemental iron/kg/day) or placebo (equivalent
volume) twice daily for four months. Children in both the
oral iron and placebo groups are also given nutritional
guidance to improve iron intake which includes recom-
mendations on the varied sources of high iron containing
foods, foods that increase and inhibit iron absorption, and
dietary habits that may prevent iron deficiency (such as -
maximum daily cow’s milk intake, limiting the intake of
juice). Concomitant interventions permitted include over
the counter multivitamins which do not contain iron;
those prohibited include additional over the counter iron
and prescription iron.
Primary outcome and measures
The primary outcome for the OptEC trial is the Early
Learning Composite (ELC) assessed using the Mullen
Scales of Early Learning (MSEL) [15]. The MSEL mea-
sures five distinct developmental skills, gross motor and
four “cognitive” skills - fine motor, visual reception, recep-
tive language, and expressive language. The four cognitive
skills are summarized and converted into age adjusted
normalized ELC, which has a mean of 100 and a standard
deviation of 15. Developmental assessment using the
MSEL is performed at baseline and after 4 months of
intervention by a trained psychometrist under the supervi-
sion of a registered psychologist. All individuals involved
with data collection, entry and analysis are blind to the
group assignment.
Collection of other variables
Baseline data collection for the internal pilot included age
and sex of child, birth weight, weight, length/height, ma-
ternal ethnicity and education, family income and some
nutritional behavior characteristics (total duration of
breastfeeding, volume of cow’s milk intake and current
bottle feeding). These data were collected using a parent-
completed, standardized data collection form based on
questions used in the Canadian Community Health
Survey. We dichotomized family income based on median
income of families in the city of Toronto [16].
Adherence related data were collected during the
4 month follow-up visit which included reasons for non-
adherence, adverse effects and a parent reported weekly
rate of days the study intervention was not taken.
Sample size for the internal pilot study
The minimum size for an internal pilot study should be
at least 10 subjects per treatment group, for a two grouprandomized trial [4]. The pre-planned sample size for
the OptEC trial ranged from 112–198 (approximately
150 subjects) [1]. The first 15 participants per treatment
group enrolled in the OptEC trial were considered as
the internal pilot study (total n = 30).
Statistical methods for the internal pilot study
For estimation of parameters for sample size recalcu-
lation, descriptive statistics of the 4 month follow-up de-
velopmental data were assessed within each treatment
group. The observed standard deviation of the ELC
score within each treatment group was pooled to obtain
an estimated standard deviation (S2) of the ELC score
(Additional file 1 shows the formula for calculating the
pooled standard deviation) [3, 17].
Recalculation of the sample size was performed using
the analysis of covariance (ANCOVA) method which
uses the design factor (or variance deflation factor) to
calculate the sample size [7]. The design factor is (1- ρ2),
where ρ is the correlation between the baseline and
follow-up measurement of the primary outcome. The
ANCOVA uses a two-step method to calculate sample
size [7]. Step 1: First, a sample size is determined using
the two sample independent t-test and the new estimate
of the SD (S2). Step 2: Then, the correlation (ρ) between
the baseline and 4 month follow-up measure of the ELC
is calculated using Pearson’s correlation. This value is
used to determine the design factor (1- ρ2). The value of
the sample sizes calculated using the t-test is then multi-
plied by the design factor (1-ρ2) to produce the number
of participants (Nr) required by the ANCOVA method.
The reasons for non-adherence were identified and
summarized. Adherence rate was calculated using a
method proposed by Klerk et al. [18]. In this method,
summaries such as - the total number of days per week
the child received the study intervention, the length of the
monitored interval and the over-all percentage of the
study intervention taken during the monitored interval
was used to calculate a rate of adherence. Furthermore,
adherence rate was described by placing participants into
broad bands of adherence. The adherence bands corre-
sponded to the number of days per week the participants
received the intervention, such as, ≥6 days correspond to
86 % - 100 % adherence; 4–5 days to 57 % - 85 %; 2–3
days to 28 % - 56 %; and ≤1 day to 0 – 27 %. The percent-
age of children in each band was also determined.
For the purpose of the internal pilot study, the two treat-
ment groups were identified as group A and group B by a
third party, so as to keep group assignment blinded to all
persons associated with the internal pilot study. Statistical
analyses were performed using SAS software version 9.1
(SAS Institute, Cary NC) and sample size calculation was
performed using the Vanderbilt University, Department of
Biostatistics, power and sample size calculator [19].
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The OptEC trial was granted ethics approval by The
Hospital for Sick Children Research Ethics Board (REB
File No.: 1000027782) on May 10, 2012 and approval is
renewed annually by the REB. Written informed consent
is obtained from parents of all child participants (including
the internal pilot study) prior to any data collection.
Criteria for success of the internal pilot study
Pre-specified criteria for success [14] for recalculation of
the sample size were as follows: if the estimated SD S2 ≤
15, the trial would continue as planned, that is the initial
sample size (Na = 112–198) will not change. However, if
the estimated SD, S2 > 15, then the sample size will be
recalculated [3]. For adherence related data, we pro-
jected that 40 % of the participants in the internal pilot
study will have 86 % - 100 % of adherence (the highest
band of adherence). There was no stopping rule for the
internal pilot study that would halt the OptEC trial.
Results
Participant flow and baseline characteristics
A total of 107 children with NAID were identified between
June, 2012 and June, 2014. Of these children ultimately a
total of 30 were randomized to the two intervention groups
(see Fig. 1: participant flow diagram). Table 1 depicts theFig. 1 Participant flow diagram for the internal pilot studybaseline characteristics of the participants in the internal
pilot of the OptEC trial.
Estimation of the standard deviation (S2) and
recalculation of the sample size
Table 2 shows the SD of the follow-up developmental
data. The SD of the ELC in group A and group B was
21.17 and 12.05, respectively. These two values were
pooled to calculate an estimated SD, S2 = 17.4. However,
we observed a large difference between the SDs of the
two treatment groups. An F-test was performed, where
we were unable to reject the null hypothesis that the
variances were equal (F value = 3.09 and p = 0.06) [17].
Therefore, the pooled estimate of the SD (S2) was used
to recalculate the sample size.
Using a significance level of 5 %, a power of 80 %, SD
value of S2 = 17.4 and clinically meaningful effect estimate
ranging from 6–8 points, a range of sample sizes were cal-
culated first using the t-test method (see Table 3). Correl-
ation (ρ) between the ELC measured at baseline and
4 month follow-up was 0.89. Hence, the design factor for
assessment of the ELC was, (1- ρ2) = 0.21. Then, following
the ANCOVA method for calculating sample size, the de-
sign factor was multiplied to the values of the sample size
calculated using the t-test and a range of sample sizes for
the OptEC trial was recalculated (Nr = 32–56) (see Table 3).
Table 1 Baseline characteristics of the children in the internal
pilot study (N = 30)
Variables names Descriptive data
Age of child (months) 23.5 (6.95)a
Sex of child Male 15 (50)b
Female 15 (50)b
zBMI of child 0.49 (0.93)a
Birth weight (kg) 3.3 (0.43)a
Maternal ethnicity European 20 (74.07)b
Non-European 7 (25.93)b




High School 2 (7.41)b
Family incomec Above median income 22 (81.48)b




Volume of cow’s milk
(cups/day)
2.46 (1. 20)b
Currently use bottle Yes 11 (42.31)b
No 15 (57.69)b
Serum ferritin (μg/L) 8.90 (2.47)a
Hemoglobin (g/L) 120.48 (9.34)a
amean (SD)
bn (%)
cIncome based on median income of families in the city of Toronto [11]




α = 5 %; 1-β = 80 %; and S2 = 17.4
Δ = 8 Δ = 7 Δ = 6
Using t-test 150 196 266
Multiplication by the design factor (1- ρ2) = 0.21
Using ANCOVA 32 42 56
α significance level, 1-β power, S2 SD, Δ effect estimate
Table 4 Adherence rates of participants in the internal pilot
study (N = 27)
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The main reasons for non-adherence among the internal
pilot sample were - the study drug takes too long to ad-
minister, is too messy, child did not like it, too difficult
to administer and forgot to give the study drug. Adverse
effects reported by the parents included vomiting (19 %),
staining of teeth (34 %), constipation (38 %), loose stool
(35 %) and passage of black stool (46 %). We found ad-
herence to the study intervention to range between 14 %
and 100 %. We then identified the number and propor-
tion of children in each adherence band (see Table 4).
The highest adherence band (86 % - 100 %) had a total
of 12 (44 %) children.
Discussion
This internal pilot study allowed a data-driven recalcu-
lation of the sample size for a randomized controlledTable 2 Follow-up developmental data of the participants in
the internal pilot study
Developmental score Group A n = 14 Group B n = 13
SD SD
Early Learning Composite (ELC) 21.17 12.05
SD standard deviationtrial. If knowledge about the standard deviation of the
primary endpoint is weak, this type of approach is super-
ior to an ordinary fixed sample design, because the ini-
tial sample size can be appropriately adjusted.
According to our first objective, an estimate of the SD
(S2 = 17.4) of the primary endpoint was determined by
pooling the observed SD in the two treatment groups
(Table 2). This estimate was found to be larger than the
SD (S1 = 15) we used to calculate the initial sample of
the OptEC trial. Hence, as stated in our criteria of suc-
cess, the new estimate of the SD was used to recalculate
the sample size.
Our second objective, recalculation of the sample size
involved the application of the ANCOVA method [7]. This
method requires the estimation of the design factor that
accounts for the correlation between the baseline and
follow-up assessment of the primary outcome, our third
objective. We determined the design factor [(1- ρ2) = 0.21]
using data from the internal pilot study. The sample sizes
calculated using the ANCOVA method ranged between
32–56 subjects which will have the same power as the
sample sizes calculated using the t-test (150–266), despite
being considerably smaller (see Table 3) [7]. In situations
where recruitment of participants is a challenge, applica-
tion of the ANCOVA method is a valid approach to
minimize the sample size in clinical trials without affecting
the power of the trial. In our OptEC trial, we aim to enroll
a total of 56 participants (28/group), in order to detect a
treatment difference of 6 points in the ELC score.
Our fourth objective was to determine the adherence
rate in our internal pilot study. According to previous evi-
dence ≥90 % of adherence in 40 % of participants was
shown to be ideal for effectiveness assessment [10]. Since
our adherence assessment was based on the number ofBands of adherence
rate (%)
Number of participants
in each band (n)
Percentage of participants
in each band (%)
86 - 100 12 44.44
57 - 85 6 22.22
28 - 56 2 7.41
0 - 27 7 25.93
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our study team modified this criteria for success to ≥86 %
adherence, as this corresponds to ≥6 days in a week. In our
study we found 44 % of participants having an adherence
rate ≥86 % (see Table 4). We believe this level of adherence
will be sufficient to meet the objective of the OptEC trial
to assess the effectiveness of the study intervention.
Because some children had adherence rate as low as
14 %, we have implemented strategies to improve adher-
ence, such as - informing parents on possible adverse ef-
fects, decreasing the dose of the study intervention when
children experience adverse effects like vomiting and diar-
rhea, counseling parents on minimizing the difficulty of
giving the study intervention and motivating parents on
continuing the study intervention when children experi-
ence non-harmful and reversible adverse effects like pas-
sage of black stool and staining of teeth. This information
has been incorporated into a participant information
handout which is given to parents when they agree to en-
roll their child in the OptEC trial.
At the end of the trial, participants in the internal pilot
study will contribute to the overall sample and outcome
analysis of the full trial. According to internal pilot
methodology, this inclusion will have minimal impact on
the significance level of the test of treatment effect [4].
The adherence rate reported in this study may be an
overestimate of the actual adherence, due to the fact that
it was based on parent reported measures.
Conclusion
Information generated from our internal pilot study was
used to update the currently ongoing OptEC trial. It not
only provided us with a more reliable and representative
estimate of the SD of the primary outcome, but also pro-
vided us with the necessary parameters needed to calculate
our sample size using the ANCOVA method. Furthermore,
our study depicts other valid uses of internal pilot data
such as the estimation of adherence rate. The internal pilot
design is one of the methods suggested by the StaR (Stan-
dards for Research in Child Health) standard development
groups to overcome challenges faced when attempting to
derive sample size estimates in pediatric research [20]. The
data generated from our internal pilot can inform future
trials to be performed in similar population, particularly
those in developed country settings.
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